FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562471572> ?p ?o ?g. }

• W2562471572 abstract "Abstract Abstract 732 Background Carfilzomib (CFZ) is an irreversible proteasome inhibitor with potent anti-MM effects and significantly decreased peripheral neuropathy rates compared with bortezomib. In this single stage phase II trial, we plan to treat 45 newly diagnosed MM patients with 8 cycles of CRd followed by 1 year of Lenalidomide (LEN) maintenance. Unique to this study, transplant eligible patients default to “delayed” ASCT per protocol and depth of molecular responses are assessed using studies of minimal residual disease (MRD) (flow cytometry, PCR, and FDG PET-CT). Using this approach, we report the first n=18/45 patient results, showing that CRd induces rapid and deep remissions. Methods Untreated newly diagnosed non-transplant and transplant candidates are eligible for protocol. Patients are administered eight 28-day cycles of therapy including: CFZ IV 20/36 mg/m2 on days 1, 2, 8, 9, 15, 16; LEN oral 25 mg days 1–21; and Dexamethasone IV/oral 20/10 mg on days 1, 2, 8, 9, 15, 16, 22, 23. Transplant eligible patients default to “delayed” ASCT approach per protocol by harvesting and cryopreserving stem cells after 4 cycles of CRd and continuing with cycles 5–8 of CRd thereafter. After 8 cycles of CRd, all patients with SD or better receive cycles 9–20 of LEN maintenance 10 mg days 1–21. Primary endpoint is the incidence of ≥ grade 3 neuropathy. Secondary endpoints include response rate, profiling CFZ activity to biological endpoints, and impact of MRD studies on clinical outcomes. Bone marrow samples are collected at baseline, C1D2 (single agent CFZ exposed), CR /end of cycle 8 (cycles 1–8), and CR/end of cycle 20 (cycles 9–20). MRD studies are performed on achievement of CR/end of cycle 8 (during cycles 1–8) and CR/end of cycle 20 (during cycles 9–20). Results 18 patients meeting eligibility criteria have been enrolled (10 male, 8 female; median age 60; range 42–83). Among the patients enrolled, mean M- protein 2.9 g/dL (1.0–7.2 g/dL) and isotypes included 10 IgG, 4 IgA, and 4 light chain only. 15 patients were evaluated for toxicity and response. No patients have reported ≥ grade 3 neuropathy. After completing one cycle, the mean decline in M-protein (heavy chain, n= 10 IgG + 4 IgA) and involved – uninvolved light chains (light chain only, n=4) was 74% and 73%, respectively. Best responses after median of 4 cycles of CRd (range 1–8) completed, include 4 – sCR/2-nCR (40%), 5 – VGPR (33%), 3 – PR (20%), and 1 – SD (6%). For patients who achieved sCR, median time from initiation of CRd treatment to sCR was 5 cycles. Four patients with sCR had no evidence of immunophenotypic abnormal plasma cells on multiparametric flow cytometry during MRD assesment. In addition, PET-CT results for 3 out of 4 sCR patients showed substantial decrease in max standardized uptake value (SUV) avid lytic lesion seen at MRD assessment when compared with baseline (average SUV decline was 76%). 1 sCR patient did not have any FDG avid lesions at baseline. All patients maintained their best response and have no evidence of clinical disease progression. 4 patients completed 8 cycles of CRd, while 3 (2 sCR and 1 SD) continued to maintenance Len phase and 1 opted to exit study after achieving sCR. The patient with only SD (17p deletion on FISH at baseline) achieved a 65% decrease in plasma cell tumor burden in bone marrow and no evidence of disease progression after 10 cycles of therapy. Patients with non-hematologic toxicity events (≥ grade3) include: 3 (20%) - hypophosphatemia, 2 (13%) - ALT increase, 2 (13%) – CHF, 1 (6%) – fatigue, 1 (6%) - anxiety, 1 – (6%) syncope, and 1(6%) – rash. Patients with ≥ grade 3 hematologic toxicity events include 10 (66%) – lymphopenia and 1 (6%) - thrombocytopenia. Updated results on additional patients and molecular/MRD studies (flow cytometry, PCR, and FDG PET-CT) will be presented at meeting. Conclusions Using an approach that merges functional imaging with molecular responses beyond traditional clinical biomarkers, we show that CRd followed by LEN maintenance and delayed ASCT is a highly potent and tolerable combination regimen in newly diagnosed MM patients. Disclosures: Off Label Use: In the clinical trial, we are using Carfilzomib in newly diagnosed multiple myeloma in combination with Lenalidomide and Dexamethasone. Currently, its label indication is single agent for use in relapsed/refractory multiple myeloma." @default.
• W2562471572 created "2017-01-06" @default.
• W2562471572 creator A5010930696 @default.
• W2562471572 creator A5014636271 @default.
• W2562471572 creator A5016656825 @default.
• W2562471572 creator A5017057018 @default.
• W2562471572 creator A5017956721 @default.
• W2562471572 creator A5024701461 @default.
• W2562471572 creator A5032718078 @default.
• W2562471572 creator A5044239219 @default.
• W2562471572 creator A5044366730 @default.
• W2562471572 creator A5044681793 @default.
• W2562471572 creator A5046553822 @default.
• W2562471572 creator A5046878636 @default.
• W2562471572 creator A5058021865 @default.
• W2562471572 creator A5061379753 @default.
• W2562471572 creator A5062086023 @default.
• W2562471572 creator A5065696086 @default.
• W2562471572 creator A5067074464 @default.
• W2562471572 creator A5079704265 @default.
• W2562471572 creator A5081833588 @default.
• W2562471572 creator A5082004555 @default.
• W2562471572 creator A5082080836 @default.
• W2562471572 creator A5089952063 @default.
• W2562471572 date "2012-11-16" @default.
• W2562471572 modified "2023-09-27" @default.
• W2562471572 title "Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients" @default.
• W2562471572 doi "https://doi.org/10.1182/blood.v120.21.732.732" @default.
• W2562471572 hasPublicationYear "2012" @default.
• W2562471572 type Work @default.
• W2562471572 sameAs 2562471572 @default.
• W2562471572 citedByCount "7" @default.
• W2562471572 countsByYear W25624715722013 @default.
• W2562471572 countsByYear W25624715722014 @default.
• W2562471572 countsByYear W25624715722015 @default.
• W2562471572 countsByYear W25624715722020 @default.
• W2562471572 countsByYear W25624715722021 @default.
• W2562471572 crossrefType "journal-article" @default.
• W2562471572 hasAuthorship W2562471572A5010930696 @default.
• W2562471572 hasAuthorship W2562471572A5014636271 @default.
• W2562471572 hasAuthorship W2562471572A5016656825 @default.
• W2562471572 hasAuthorship W2562471572A5017057018 @default.
• W2562471572 hasAuthorship W2562471572A5017956721 @default.
• W2562471572 hasAuthorship W2562471572A5024701461 @default.
• W2562471572 hasAuthorship W2562471572A5032718078 @default.
• W2562471572 hasAuthorship W2562471572A5044239219 @default.
• W2562471572 hasAuthorship W2562471572A5044366730 @default.
• W2562471572 hasAuthorship W2562471572A5044681793 @default.
• W2562471572 hasAuthorship W2562471572A5046553822 @default.
• W2562471572 hasAuthorship W2562471572A5046878636 @default.
• W2562471572 hasAuthorship W2562471572A5058021865 @default.
• W2562471572 hasAuthorship W2562471572A5061379753 @default.
• W2562471572 hasAuthorship W2562471572A5062086023 @default.
• W2562471572 hasAuthorship W2562471572A5065696086 @default.
• W2562471572 hasAuthorship W2562471572A5067074464 @default.
• W2562471572 hasAuthorship W2562471572A5079704265 @default.
• W2562471572 hasAuthorship W2562471572A5081833588 @default.
• W2562471572 hasAuthorship W2562471572A5082004555 @default.
• W2562471572 hasAuthorship W2562471572A5082080836 @default.
• W2562471572 hasAuthorship W2562471572A5089952063 @default.
• W2562471572 hasConcept C126322002 @default.
• W2562471572 hasConcept C126894567 @default.
• W2562471572 hasConcept C141071460 @default.
• W2562471572 hasConcept C143998085 @default.
• W2562471572 hasConcept C203092338 @default.
• W2562471572 hasConcept C2776063141 @default.
• W2562471572 hasConcept C2776364478 @default.
• W2562471572 hasConcept C2776694085 @default.
• W2562471572 hasConcept C2777478702 @default.
• W2562471572 hasConcept C2778822529 @default.
• W2562471572 hasConcept C2779823535 @default.
• W2562471572 hasConcept C2780007613 @default.
• W2562471572 hasConcept C2780108899 @default.
• W2562471572 hasConcept C2780401358 @default.
• W2562471572 hasConcept C535046627 @default.
• W2562471572 hasConcept C71924100 @default.
• W2562471572 hasConcept C90924648 @default.
• W2562471572 hasConceptScore W2562471572C126322002 @default.
• W2562471572 hasConceptScore W2562471572C126894567 @default.
• W2562471572 hasConceptScore W2562471572C141071460 @default.
• W2562471572 hasConceptScore W2562471572C143998085 @default.
• W2562471572 hasConceptScore W2562471572C203092338 @default.
• W2562471572 hasConceptScore W2562471572C2776063141 @default.
• W2562471572 hasConceptScore W2562471572C2776364478 @default.
• W2562471572 hasConceptScore W2562471572C2776694085 @default.
• W2562471572 hasConceptScore W2562471572C2777478702 @default.
• W2562471572 hasConceptScore W2562471572C2778822529 @default.
• W2562471572 hasConceptScore W2562471572C2779823535 @default.
• W2562471572 hasConceptScore W2562471572C2780007613 @default.
• W2562471572 hasConceptScore W2562471572C2780108899 @default.
• W2562471572 hasConceptScore W2562471572C2780401358 @default.
• W2562471572 hasConceptScore W2562471572C535046627 @default.
• W2562471572 hasConceptScore W2562471572C71924100 @default.
• W2562471572 hasConceptScore W2562471572C90924648 @default.
• W2562471572 hasLocation W25624715721 @default.
• W2562471572 hasOpenAccess W2562471572 @default.
• W2562471572 hasPrimaryLocation W25624715721 @default.
• W2562471572 hasRelatedWork W137122611 @default.
• W2562471572 hasRelatedWork W1706075570 @default.
• W2562471572 hasRelatedWork W1968769311 @default.

• next